These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 2043283)
21. Management of protease inhibitor-associated hyperlipidemia. Penzak SR; Chuck SK Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985 [TBL] [Abstract][Full Text] [Related]
22. Hyperlipidemia. What to do when life-style changes aren't enough. Peters WL Postgrad Med; 1991 Oct; 90(5):213-7, 220-4. PubMed ID: 1924009 [TBL] [Abstract][Full Text] [Related]
23. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients. Lal SM; Katyal A Mo Med; 2002; 99(10):580-4. PubMed ID: 12534147 [TBL] [Abstract][Full Text] [Related]
24. [Drugs in hyperlipidemia]. Stuyt PM Ned Tijdschr Geneeskd; 1987 Sep; 131(36):1554-8. PubMed ID: 3670435 [No Abstract] [Full Text] [Related]
25. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Malhotra HS; Goa KL Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468 [TBL] [Abstract][Full Text] [Related]
26. Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270 [TBL] [Abstract][Full Text] [Related]
27. Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588 [TBL] [Abstract][Full Text] [Related]
29. Should pediatric patients with hyperlipidemia receive drug therapy? Bhatnagar D Paediatr Drugs; 2002; 4(4):223-30. PubMed ID: 11960511 [TBL] [Abstract][Full Text] [Related]
30. Effects and side-effects of treatment of hypercholesterolemia with cholestyramine and neomycin. Faergeman O Acta Med Scand; 1973; 194(3):165-7. PubMed ID: 4746523 [No Abstract] [Full Text] [Related]
32. Treating hyperlipidemia, Part III: Drug therapy. Smith DA; Karmally W; Brown WV Geriatrics; 1987 Aug; 42(8):55-9, 62. PubMed ID: 3110017 [TBL] [Abstract][Full Text] [Related]
33. Drug treatment of dyslipoproteinemia. Larsen ML; Illingworth DR Med Clin North Am; 1994 Jan; 78(1):225-45. PubMed ID: 8283933 [TBL] [Abstract][Full Text] [Related]
34. Management of hyperlipidemia: goals for the prevention of atherosclerosis. Illingworth DR Clin Invest Med; 1990 Aug; 13(4):211-8. PubMed ID: 2208837 [TBL] [Abstract][Full Text] [Related]
35. Comparative tolerability of the HMG-CoA reductase inhibitors. Farmer JA; Torre-Amione G Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703 [TBL] [Abstract][Full Text] [Related]
36. How well tolerated are lipid-lowering drugs? Tomlinson B; Chan P; Lan W Drugs Aging; 2001; 18(9):665-83. PubMed ID: 11599634 [TBL] [Abstract][Full Text] [Related]
37. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia. Orö L; Olsson AG; Rössner S; Carlson LA Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986 [TBL] [Abstract][Full Text] [Related]
39. Prevalence of gallstones in hyperlipidemia and incidence during treatment with clofibrate and/or cholestyramine. Palmer RH Trans Assoc Am Physicians; 1978; 91():424-32. PubMed ID: 754401 [TBL] [Abstract][Full Text] [Related]
40. Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels. LaRosa J Cardiology; 1989; 76 Suppl 1():55-61; discussion 61-4. PubMed ID: 2653624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]